 LEXINGTON, Mass., Aug. 10, 2021 PRNewswire -- Pulmatrix, Inc. NASDAQ: PULM, a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSETM technology, today reports its second quarter 2021 financial results and provides a business update. 